Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities
The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells. The NP was prepared by nanoprecipitation and characterized the particle size, charge, entrapment of drug and relea...
Gespeichert in:
| Veröffentlicht in: | PloS one 2018-11, Vol.13 (11), p.e0206109-e0206109 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0206109 |
|---|---|
| container_issue | 11 |
| container_start_page | e0206109 |
| container_title | PloS one |
| container_volume | 13 |
| creator | Venugopal, Vijayan Krishnan, Shalini Palanimuthu, Vasanth Raj Sankarankutty, Subin Kalaimani, Jayaraja Kumar Karupiah, Sundram Kit, Ng Siew Hock, Tang Thean |
| description | The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells. The NP was prepared by nanoprecipitation and characterized the particle size, charge, entrapment of drug and release of it. The anti-EGFR anchored and the integrity was confirmed by SDS-PAGE. Cytotoxicity and NPs cellular uptake was analyzed with MDA-MB-468 type cancer cells and the EGFR expression was confirmed by PCR, qualitatively and quantitatively. The in-vivo antitumor activity of INP was determined by using athymic mice model and targeting efficiency was measured by calculating the PTX accumulation in the tumor plasma. The prepared INP with the size of 336.3 nm and the charge of -3.48 mV showed sustained drug release upto 48 h. The INP showed significant reduction of cancer cell viability of 10.6% for 48 h with 93 fold higher PTX accumulation in the tumor plasma compared with NPs. Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC. |
| doi_str_mv | 10.1371/journal.pone.0206109 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2131221866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_44c03fae9e23451c94590946d4b172bb</doaj_id><sourcerecordid>2131221866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-93e9c8e8b690e3f95a654010d0cd0cbb8006143c69ee95fc96afde22fd8192b63</originalsourceid><addsrcrecordid>eNptUl2LEzEUHURx19V_IBrwxZep-Zrs5EUoy24tFBTR55DJ3GmzpMmYpGX9I_5e03Z22RUhkPtx7rn3Hm5VvSV4Rtgl-XQbdtFrNxuDhxmmWBAsn1XnRDJaC4rZ80f2WfUqpVuMG9YK8bI6Y5jjFov2vPoz99nW14ub70h7swkRejRq42zWd-CQC7ovkW-rxRx57cOoY7bGQUJDiChvAOUIOm_BZxSG4tjRAfKw1tnuAXUlmTIyhRriDC19vbc5htKqR_bg7A92YTwCkDalymYL6XX1YtAuwZvpv6h-3lz_uPpSr74ullfzVW0aKnItGUjTQtsJiYENstGi4ZjgHpvyuq7FRRbOjJAAshmMFHrogdKhb4mknWAX1fsT7-hCUpOkSVHCCKWkiFUQyxOiD_pWjdFudfytgrbqGAhxrSZNFOcGs0GDBMp4Q4zkjcSSi5535JJ2XeH6PHXbdVvoTVEtaveE9GnG241ah70SlHLMcCH4OBHE8GsHKautTQac0x7C7jh3QZICL9AP_0D_vx0_oUwMKUUYHoYhWB3O7L5KHc5MTWdWyt49XuSh6P6u2F-aDtJg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2131221866</pqid></control><display><type>article</type><title>Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities</title><source>MEDLINE</source><source>Public Library of Science</source><source>Free E-Journal (出版社公開部分のみ）</source><source>PubMed Central</source><source>Directory of Open Access Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Venugopal, Vijayan ; Krishnan, Shalini ; Palanimuthu, Vasanth Raj ; Sankarankutty, Subin ; Kalaimani, Jayaraja Kumar ; Karupiah, Sundram ; Kit, Ng Siew ; Hock, Tang Thean</creator><contributor>Xu, Bing</contributor><creatorcontrib>Venugopal, Vijayan ; Krishnan, Shalini ; Palanimuthu, Vasanth Raj ; Sankarankutty, Subin ; Kalaimani, Jayaraja Kumar ; Karupiah, Sundram ; Kit, Ng Siew ; Hock, Tang Thean ; Xu, Bing</creatorcontrib><description>The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells. The NP was prepared by nanoprecipitation and characterized the particle size, charge, entrapment of drug and release of it. The anti-EGFR anchored and the integrity was confirmed by SDS-PAGE. Cytotoxicity and NPs cellular uptake was analyzed with MDA-MB-468 type cancer cells and the EGFR expression was confirmed by PCR, qualitatively and quantitatively. The in-vivo antitumor activity of INP was determined by using athymic mice model and targeting efficiency was measured by calculating the PTX accumulation in the tumor plasma. The prepared INP with the size of 336.3 nm and the charge of -3.48 mV showed sustained drug release upto 48 h. The INP showed significant reduction of cancer cell viability of 10.6% for 48 h with 93 fold higher PTX accumulation in the tumor plasma compared with NPs. Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0206109</identifier><identifier>PMID: 30408068</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Accumulation ; Animals ; Anticancer properties ; Antitumor activity ; Biocompatibility ; Biology and Life Sciences ; Breast cancer ; Cancer ; Cancer therapies ; Cell cycle ; Cell Line, Tumor ; Cell Survival - drug effects ; Chemotherapy ; Computing time ; Cytotoxicity ; Delayed-Action Preparations ; Drug Carriers - administration & dosage ; Drug Carriers - chemistry ; Drug delivery systems ; Engineering and Technology ; Entrapment ; Epidermal growth factor ; Epidermal growth factor receptors ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - chemistry ; Gel electrophoresis ; Humans ; Medical prognosis ; Medical research ; Medicine and Health Sciences ; Mice ; Nanoparticles ; Nanoparticles - administration & dosage ; Nanoparticles - chemistry ; Paclitaxel ; Paclitaxel - administration & dosage ; Paclitaxel - chemistry ; Pharmaceutical sciences ; Pharmacy ; Physical Sciences ; Plasma ; Polylactic Acid-Polyglycolic Acid Copolymer ; Polylactide-co-glycolide ; Proteins ; Research and Analysis Methods ; Side effects ; Sodium lauryl sulfate ; Toxicity ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - pathology ; Tumors ; Xenograft Model Antitumor Assays</subject><ispartof>PloS one, 2018-11, Vol.13 (11), p.e0206109-e0206109</ispartof><rights>2018 Venugopal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Venugopal et al 2018 Venugopal et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-93e9c8e8b690e3f95a654010d0cd0cbb8006143c69ee95fc96afde22fd8192b63</citedby><orcidid>0000-0002-7320-7390 ; 0000-0002-3861-9787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224030/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224030/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30408068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Xu, Bing</contributor><creatorcontrib>Venugopal, Vijayan</creatorcontrib><creatorcontrib>Krishnan, Shalini</creatorcontrib><creatorcontrib>Palanimuthu, Vasanth Raj</creatorcontrib><creatorcontrib>Sankarankutty, Subin</creatorcontrib><creatorcontrib>Kalaimani, Jayaraja Kumar</creatorcontrib><creatorcontrib>Karupiah, Sundram</creatorcontrib><creatorcontrib>Kit, Ng Siew</creatorcontrib><creatorcontrib>Hock, Tang Thean</creatorcontrib><title>Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells. The NP was prepared by nanoprecipitation and characterized the particle size, charge, entrapment of drug and release of it. The anti-EGFR anchored and the integrity was confirmed by SDS-PAGE. Cytotoxicity and NPs cellular uptake was analyzed with MDA-MB-468 type cancer cells and the EGFR expression was confirmed by PCR, qualitatively and quantitatively. The in-vivo antitumor activity of INP was determined by using athymic mice model and targeting efficiency was measured by calculating the PTX accumulation in the tumor plasma. The prepared INP with the size of 336.3 nm and the charge of -3.48 mV showed sustained drug release upto 48 h. The INP showed significant reduction of cancer cell viability of 10.6% for 48 h with 93 fold higher PTX accumulation in the tumor plasma compared with NPs. Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC.</description><subject>Accumulation</subject><subject>Animals</subject><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Biocompatibility</subject><subject>Biology and Life Sciences</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Chemotherapy</subject><subject>Computing time</subject><subject>Cytotoxicity</subject><subject>Delayed-Action Preparations</subject><subject>Drug Carriers - administration & dosage</subject><subject>Drug Carriers - chemistry</subject><subject>Drug delivery systems</subject><subject>Engineering and Technology</subject><subject>Entrapment</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - chemistry</subject><subject>Gel electrophoresis</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Mice</subject><subject>Nanoparticles</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - chemistry</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacy</subject><subject>Physical Sciences</subject><subject>Plasma</subject><subject>Polylactic Acid-Polyglycolic Acid Copolymer</subject><subject>Polylactide-co-glycolide</subject><subject>Proteins</subject><subject>Research and Analysis Methods</subject><subject>Side effects</subject><subject>Sodium lauryl sulfate</subject><subject>Toxicity</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Tumors</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNptUl2LEzEUHURx19V_IBrwxZep-Zrs5EUoy24tFBTR55DJ3GmzpMmYpGX9I_5e03Z22RUhkPtx7rn3Hm5VvSV4Rtgl-XQbdtFrNxuDhxmmWBAsn1XnRDJaC4rZ80f2WfUqpVuMG9YK8bI6Y5jjFov2vPoz99nW14ub70h7swkRejRq42zWd-CQC7ovkW-rxRx57cOoY7bGQUJDiChvAOUIOm_BZxSG4tjRAfKw1tnuAXUlmTIyhRriDC19vbc5htKqR_bg7A92YTwCkDalymYL6XX1YtAuwZvpv6h-3lz_uPpSr74ullfzVW0aKnItGUjTQtsJiYENstGi4ZjgHpvyuq7FRRbOjJAAshmMFHrogdKhb4mknWAX1fsT7-hCUpOkSVHCCKWkiFUQyxOiD_pWjdFudfytgrbqGAhxrSZNFOcGs0GDBMp4Q4zkjcSSi5535JJ2XeH6PHXbdVvoTVEtaveE9GnG241ah70SlHLMcCH4OBHE8GsHKautTQac0x7C7jh3QZICL9AP_0D_vx0_oUwMKUUYHoYhWB3O7L5KHc5MTWdWyt49XuSh6P6u2F-aDtJg</recordid><startdate>20181108</startdate><enddate>20181108</enddate><creator>Venugopal, Vijayan</creator><creator>Krishnan, Shalini</creator><creator>Palanimuthu, Vasanth Raj</creator><creator>Sankarankutty, Subin</creator><creator>Kalaimani, Jayaraja Kumar</creator><creator>Karupiah, Sundram</creator><creator>Kit, Ng Siew</creator><creator>Hock, Tang Thean</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7320-7390</orcidid><orcidid>https://orcid.org/0000-0002-3861-9787</orcidid></search><sort><creationdate>20181108</creationdate><title>Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities</title><author>Venugopal, Vijayan ; Krishnan, Shalini ; Palanimuthu, Vasanth Raj ; Sankarankutty, Subin ; Kalaimani, Jayaraja Kumar ; Karupiah, Sundram ; Kit, Ng Siew ; Hock, Tang Thean</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-93e9c8e8b690e3f95a654010d0cd0cbb8006143c69ee95fc96afde22fd8192b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Accumulation</topic><topic>Animals</topic><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Biocompatibility</topic><topic>Biology and Life Sciences</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Chemotherapy</topic><topic>Computing time</topic><topic>Cytotoxicity</topic><topic>Delayed-Action Preparations</topic><topic>Drug Carriers - administration & dosage</topic><topic>Drug Carriers - chemistry</topic><topic>Drug delivery systems</topic><topic>Engineering and Technology</topic><topic>Entrapment</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - chemistry</topic><topic>Gel electrophoresis</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Mice</topic><topic>Nanoparticles</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - chemistry</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacy</topic><topic>Physical Sciences</topic><topic>Plasma</topic><topic>Polylactic Acid-Polyglycolic Acid Copolymer</topic><topic>Polylactide-co-glycolide</topic><topic>Proteins</topic><topic>Research and Analysis Methods</topic><topic>Side effects</topic><topic>Sodium lauryl sulfate</topic><topic>Toxicity</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Tumors</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venugopal, Vijayan</creatorcontrib><creatorcontrib>Krishnan, Shalini</creatorcontrib><creatorcontrib>Palanimuthu, Vasanth Raj</creatorcontrib><creatorcontrib>Sankarankutty, Subin</creatorcontrib><creatorcontrib>Kalaimani, Jayaraja Kumar</creatorcontrib><creatorcontrib>Karupiah, Sundram</creatorcontrib><creatorcontrib>Kit, Ng Siew</creatorcontrib><creatorcontrib>Hock, Tang Thean</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venugopal, Vijayan</au><au>Krishnan, Shalini</au><au>Palanimuthu, Vasanth Raj</au><au>Sankarankutty, Subin</au><au>Kalaimani, Jayaraja Kumar</au><au>Karupiah, Sundram</au><au>Kit, Ng Siew</au><au>Hock, Tang Thean</au><au>Xu, Bing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2018-11-08</date><risdate>2018</risdate><volume>13</volume><issue>11</issue><spage>e0206109</spage><epage>e0206109</epage><pages>e0206109-e0206109</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells. The NP was prepared by nanoprecipitation and characterized the particle size, charge, entrapment of drug and release of it. The anti-EGFR anchored and the integrity was confirmed by SDS-PAGE. Cytotoxicity and NPs cellular uptake was analyzed with MDA-MB-468 type cancer cells and the EGFR expression was confirmed by PCR, qualitatively and quantitatively. The in-vivo antitumor activity of INP was determined by using athymic mice model and targeting efficiency was measured by calculating the PTX accumulation in the tumor plasma. The prepared INP with the size of 336.3 nm and the charge of -3.48 mV showed sustained drug release upto 48 h. The INP showed significant reduction of cancer cell viability of 10.6% for 48 h with 93 fold higher PTX accumulation in the tumor plasma compared with NPs. Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>30408068</pmid><doi>10.1371/journal.pone.0206109</doi><orcidid>https://orcid.org/0000-0002-7320-7390</orcidid><orcidid>https://orcid.org/0000-0002-3861-9787</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2018-11, Vol.13 (11), p.e0206109-e0206109 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2131221866 |
| source | MEDLINE; Public Library of Science; Free E-Journal (出版社公開部分のみ）; PubMed Central; Directory of Open Access Journals; Free Full-Text Journals in Chemistry |
| subjects | Accumulation Animals Anticancer properties Antitumor activity Biocompatibility Biology and Life Sciences Breast cancer Cancer Cancer therapies Cell cycle Cell Line, Tumor Cell Survival - drug effects Chemotherapy Computing time Cytotoxicity Delayed-Action Preparations Drug Carriers - administration & dosage Drug Carriers - chemistry Drug delivery systems Engineering and Technology Entrapment Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - chemistry Gel electrophoresis Humans Medical prognosis Medical research Medicine and Health Sciences Mice Nanoparticles Nanoparticles - administration & dosage Nanoparticles - chemistry Paclitaxel Paclitaxel - administration & dosage Paclitaxel - chemistry Pharmaceutical sciences Pharmacy Physical Sciences Plasma Polylactic Acid-Polyglycolic Acid Copolymer Polylactide-co-glycolide Proteins Research and Analysis Methods Side effects Sodium lauryl sulfate Toxicity Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - pathology Tumors Xenograft Model Antitumor Assays |
| title | Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A03%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-EGFR%20anchored%20paclitaxel%20loaded%20PLGA%20nanoparticles%20for%20the%20treatment%20of%20triple%20negative%20breast%20cancer.%20In-vitro%20and%20in-vivo%20anticancer%20activities&rft.jtitle=PloS%20one&rft.au=Venugopal,%20Vijayan&rft.date=2018-11-08&rft.volume=13&rft.issue=11&rft.spage=e0206109&rft.epage=e0206109&rft.pages=e0206109-e0206109&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0206109&rft_dat=%3Cproquest_plos_%3E2131221866%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2131221866&rft_id=info:pmid/30408068&rft_doaj_id=oai_doaj_org_article_44c03fae9e23451c94590946d4b172bb&rfr_iscdi=true |